Neurophysiological alterations in mice and humans carrying mutations in APP and PSEN1 genes.

"Declarations Ethics approval and consent to participateAll animal experiments were approved by the Central Committee for Animal Experiments and the Animal Welfare Body of the Vrije Universiteit Amsterdam in full compliance with the directive 2010/63/EU. All participants provided written informed consent for the use of their data for research purposes. Consent for publicationNot applicable. Competing interestsDr Scheltens is a full-time employee of EQT Life Sciences (formerly LSP) and Professor Emeritus at Amsterdam University Medical Centers. He has received consultancy fees (paid to the university) from Alzheon, Brainstorm Cell and Green Valley. Within his university affiliation he is global PI of the phase 1b study of AC Immune, Phase 2b study with FUJI-film/Toyama and phase 2 study of UCB. He is past chair of the EU steering committee of the phase 2b program of Vivoryon and the phase 2b study of Novartis Cardiology and presently co-chair of the phase 3 study with NOVO-Nordisk. Dr Van Kesteren serves on the Scientific Advisory Board of Alzheimer Nederland. All other authors report no competing interests. Competing interests Dr Scheltens is a full-time employee of EQT Life Sciences (formerly LSP) and Professor Emeritus at Amsterdam University Medical Centers. He has received consultancy fees (paid to the university) from Alzheon, Brainstorm Cell and Green Valley. Within his university affiliation he is global PI of the phase 1b study of AC Immune, Phase 2b study with FUJI-film/Toyama and phase 2 study of UCB. He is past chair of the EU steering committee of the phase 2b program of Vivoryon and the phase 2b study of Novartis Cardiology and presently co-chair of the phase 3 study with NOVO-Nordisk. Dr Van Kesteren serves on the Scientific Advisory Board of Alzheimer Nederland. All other authors report no competing interests."

"Funding This work was supported by the Netherlands Organization for Health Research and Development (ZonMW; grant #91218018 and grant #733050812). MEG scans were made possible by a research grant from Amsterdam Neuroscience. Dr. Gouw receives financial support from Vivoryon Therapeutics AG via the Amsterdam Alzheimer Center. Research of Amsterdam Alzheimer Center is part of the neurodegeneration program of Amsterdam Neuroscience. The Amsterdam Alzheimer Center is supported by Alzheimer Nederland and Stichting VUmc funds."